Fortis Healthcare Limited has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a significant growth in consolidated revenue to ₹9,12,784 lacs for the fiscal year, with a net profit of ₹1,06,419 lacs. The Board has recommended a final dividend of ₹1.00 per equity share (10% of face value) for the financial year 2025-26, subject to member approval.
Annual Financial Highlights
For the financial year ended March 31, 2026, Fortis Healthcare recorded a strong performance. Consolidated revenue from operations stood at ₹9,12,784 lacs, marking a notable increase from ₹7,78,275 lacs in the previous year. The consolidated net profit for the year reached ₹1,06,419 lacs, compared to ₹80,938 lacs in FY 2024-25. EBITDA for the year was reported at ₹2,13,564 lacs, reflecting solid operational efficiency.
Segment Performance
The company continues to operate two reportable segments: Healthcare and Diagnostics. The Healthcare segment contributed ₹7,77,269 lacs to total revenue, while the Diagnostics segment generated ₹1,52,656 lacs for the year. Both segments showed year-over-year revenue growth, highlighting the company’s strong market position across its diagnostic and healthcare service portfolios.
Dividend and Strategic Appointments
Reflecting its commitment to shareholder value, the Board of Directors has recommended a final dividend of ₹1.00 per equity share, representing 10% of the ₹10 face value. This payout is subject to shareholder approval at the upcoming Annual General Meeting and will be processed within 30 days thereafter. Furthermore, the company has appointed M/s Jitender, Navneet & Co. as the Cost Auditor for the financial year 2026-27 and has approved a new Corporate Social Responsibility (CSR) policy.
Operational Milestones
The company has actively expanded its footprint through strategic acquisitions, including the purchase of TMI Healthcare Private Limited (People Tree Hospital, Bengaluru) for ₹43,386 lacs. Additionally, the company is continuing to focus on integrating operations and establishment entities, supported by recent NCLT-approved schemes of arrangement, ensuring a robust structure for future growth.
Source: BSE
